Advertisement
Drug Discovery
Subscribe to Drug Discovery

The Lead

Inovio's HPV Immunotherapy Hits Primary Endpoint

July 23, 2014 2:35 pm | News | Comments

Inovio Pharmaceuticals Inc. announced successful results from Phase 2 trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Read more...         

Oral Cancer Drug May be Potential Alzheimer’s Therapy

July 23, 2014 2:26 pm | News | Comments

Scientists are now reporting new progress on a set of compounds, initially developed for cancer...

Autoimmune Disorders, Cancer Share Apoptosis Inhibitors

July 23, 2014 10:53 am | News | Comments

Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new...

Potential Flu Drugs Target Immune Response, Not Virus

July 22, 2014 2:07 pm | News | Comments

The seriousness of disease often results from the strength of immune response, rather than with...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

NIH Grants Sorrento Funding for Development of Small Molecule Inhibitor

July 21, 2014 3:57 pm | News | Comments

Sorrento Therapeutics Inc. announced that it has received non-dilutive funding for the preclinical development of a small molecule inhibitor targeting the important oncogenic transcription factor Myc. Read more…           

FDA Accepts Avanir's Trial App for Depression Drug

July 21, 2014 3:43 pm | News | Comments

Avanir Pharmaceuticals Inc. announced that the FDA accepted the company's Investigational New Drug (IND) application for a Phase 2 study assessing the safety and efficacy of AVP-786, Avanir's next generation compound. Read more...      

MetaMax Enrolls First Patients in Trial of Anticancer Drug

July 21, 2014 11:58 am | News | Comments

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. Read more...

Advertisement

JDRF, ViaCyte File IND App for Diabetes Treatment Trial

July 18, 2014 3:30 pm | News | Comments

JDRF announced that ViaCyte Inc. has filed an Investigational New Drug application (IND) with the FDA seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. Read more...                

Researchers ID Possible Target for Early-Stage Breast Cancer Immunotherapy

July 18, 2014 2:59 pm | News | Comments

Researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. Read more...                         

Unrecognized Layer of Biology Promises New Drug Targets

July 18, 2014 11:24 am | News | Comments

Scientists at The Scripps Research Institute and Hong Kong University of Science and Technology and their collaborators have found that ancient enzymes, known for their fundamental role in translating genetic information into proteins, evolved myriad other functions in humans. Read more...

Arthritis Drug Shown to Slow Alzheimer’s

July 17, 2014 1:45 pm | News | Comments

A drug that is commonly used for arthritis has been shown to slow the progression of Alzheimer’s. A small randomized control study tested the drug Etanercept on patients with mild to moderate Alzheimer’s. Read more...          

Protein Injection Halts Diabetes in Mice

July 17, 2014 1:36 pm | Videos | Comments

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery could lead to a new generation of diabetes drugs. Read more...

Advertisement

Scientists Trap, Kill Malaria Parasite

July 17, 2014 10:45 am | by Michael C. Purdy | News | Comments

Scientists may be able to entomb the malaria parasite, Plasmodium falciparum, in a prison of its own making, researchers at Washington University School of Medicine in St. Louis report in Nature, which in another story highlights the importance of a pore to the parasite’s survival. Read more...

Isis Earns $1M from GSK for Advancing ISIS-TTR Rx

July 16, 2014 1:21 pm | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million milestone payment from GSK, related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. Read more...        

New Brain Protein Tied to Alzheimer's Disease

July 16, 2014 1:01 pm | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

Scientists have linked a new protein to Alzheimer's disease, which could give a new target for developing drugs and other treatments for Alzheimer's, the most common form of dementia. Read more...                

Researchers Alleviate Pulmonary Inflammation Through Targeted Drug Delivery

July 15, 2014 2:43 pm | News | Comments

To date, no medication has been successful at preventing or mitigating the damage caused by pulmonary inflammation. Now, a research team has found that when delivered by a microscopic transporter called a nanocarrier, steroids can access the hard-to-reach lung endothelial cells that need it most and are successful at preventing inflammation in mice. Read more...

Novartis to Use Google Technology for 'Smart' Contacts

July 15, 2014 2:19 pm | News | Comments

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease. Read more...                 

Advertisement

Cannabis Compound Could Slow Tumor Growth, Research Shows

July 14, 2014 2:26 pm | News | Comments

Scientists have shown how the main psychoactive ingredient in cannabis could reduce tumor growth in cancer patients. Read more...                                   

Combo Therapy More Effective in Removing Beta-Amyloid from Mice Brains

July 14, 2014 2:19 pm | News | Comments

Eli Lilly and Co. announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE. Read more...      

Antibody Halts Cancer-Related Wasting Condition

July 14, 2014 2:05 pm | News | Comments

New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle that occurs in about half of all cancer patients, raising their risk of death. Read more...             

New Technology Delivers Cargo, Doesn’t Disrupt Cell

July 14, 2014 10:59 am | News | Comments

Portage Biotech announced that Portage Pharmaceuticals has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes that delivers an active pharmacological agent or cargo into a cell without disrupting the cell membrane. Read more...

Ipsen, Galderma Expand Neurotoxin Partnership

July 11, 2014 3:16 pm | News | Comments

Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, announced that they have significantly expanded the scope of their neurotoxin partnership. Read more...   

New Compound Treats Blindness, Diabetes in Mice

July 11, 2014 3:03 pm | News | Comments

In a new study, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. Read more...      

Girl Hoped to Have Been Cured of HIV Has Relapsed

July 11, 2014 2:51 pm | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

A Mississippi girl born with the AIDS virus and in remission for more than two years despite stopping treatment now shows signs that she still harbors HIV- and therefore is not cured. Read more...                

Scientists Advance Search for Novel Materials

July 11, 2014 11:00 am | News | Comments

Scientists at Stanford University and the Department of Energy’s SLAC National Accelerator Laboratory have found a way to estimate uncertainties in computer calculations that are widely used to speed the search for new materials for industry, electronics, energy, drug design and a host of other applications. Read more...

Addressing Side Effects of Mainstream Treatments

July 11, 2014 10:52 am | by Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus Therapeutics Inc. | Articles | Comments

The highest-profile symptoms of major diseases are well publicized, yet for many, the side effects of mainstream therapies for these diseases can also impact physical and psychological well-being. Luckily, advances in drug delivery have offered novel treatments. Read more...

JDRF, Lexicon Collaborate on Phase 2 Diabetes Trial

July 10, 2014 12:00 pm | News | Comments

Lexicon Pharmaceuticals announced that JDRF will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. Read more...   

Tiny DNA Pyramids Enter Bacteria, Deliver Deadly Payload

July 10, 2014 12:00 pm | News | Comments

Bacterial infections usually announce themselves with pain and fever but often can be defeated with antibiotics— and then there are those that are sneaky and hard to beat. Now, scientists have built a new weapon against such pathogens in the form of tiny DNA pyramids. Read more...

Vaccine Achieves Simultaneous Protection Against Ricin, Anthrax

July 10, 2014 12:00 pm | News | Comments

Soligenix Inc. announced that the combination of RiVax and VeloThrax induces protective immunity to both ricin toxin and anthrax toxin exposure. Read more...                           

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading